You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK):復必泰BNT162b2、復必泰二價疫苗均獲正式註冊為中國香港藥品/製品(生物製品)

格隆匯12月19日丨復星醫藥(02196.HK)公吿,2022年12月19日,公司控股子公司復星實業(香港)有限公司(作為復星醫藥產業的分許可方)收到《藥品/製品註冊證明書》(以下簡稱“本次註冊”),基於本次合作引進的mRNA新冠疫苗BNT162b2(以下簡稱“復必泰BNT162b2”)、原始株/Omicron變異株BA.4-5二價疫苗(以下簡稱“復必泰二價疫苗”)(以下合稱“該等疫苗”)均獲正式註冊為中國香港特別行政區(以下簡稱“中國香港”)藥品/製品(生物製品),其中,復必泰BNT162b2獲註冊用於12歲及以上人羣的基礎免疫接種、復必泰二價疫苗獲註冊用於12歲及以上人羣的加強接種。

該等疫苗本次於中國香港獲正式註冊系依據中國香港法例第138章。本次註冊後,有接種意願的人士可憑當地醫生處方於位於中國香港的醫療機構或診所接種該等疫苗(使用範圍將不再限於當地政府接種計劃下的接種)。

此前,復必泰BNT162b2、相關兒童劑型(用於5至11歲兒童接種)及幼兒劑型(用於6個月至4歲幼兒接種)、復必泰二價疫苗已分別獲中國香港緊急使用認可(EUA)用於當地政府接種計劃,並已獲中國澳門特別行政區(以下簡稱“中國澳門”)特別許可進口用於當地政府接種計劃(其中復必泰BNT162b2也已獲批准為常規進口疫苗,可憑當地醫生處方於位於中國澳門的醫療機構或診所接種)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account